P&MA Deep-Dive: To what extent are the PDx brands experiencing price erosion? In which markets is this occurring most significantly? How will health authority comparative benefit assessments affect the pricing outlook for PDx brands, and how will price erosion and the prospect of interchangeability rise in probability over time?ģ. Clinical Deep-Dive: How are the two subclasses (PD-1 / PD-L1) based on mechanism of action differentiated? How have differences in clinical trial design affected results? To what extent can manufacturers incorporate these learnings within future trials to improve regulatory, value perception, access, and pricing?Ģ. Following this post, three additional topics will be explored:ġ. First, we will explore the latest in the PDx competitive landscape as Q2 2018 comes to a close. To compete, the deluge of daily trial readouts and approvals must be monitored – and more importantly, their implications must be considered.ĬBPartners has built a strong reputation advising the commercialisation strategy of these and other oncology product categories. With more than 1,000 immuno-oncology trials underway, this high-stakes, highly-competitive space will evolve with every success and failure among manufacturers elbowing for an advantage. As new PDx near launch and existing competitors add indications, the category will have profound impact on how patient treatment plans are developed, and what their prognoses improve. However, while most of these products are slowly entering rare disease indications, the PDx class is swiftly expanding across the solid tumour field. In recent months, the oncology stage has been dominated by the arrival of CAR-Ts, the value assessment of a “cure”, and the shock of several launch prices that ranged from half to one dollars.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |